Support Alert

Antivirals and neutralising monoclonal antibodies in the treatment of Covid-19 in hospitalised Patients

A COVID-19 therapeutic alert has been issued: neutralising monoclonal antibodies (nMABs) and antivirals for treatment of Covid-19 hospitalised patients.

The policy has been updated to reflect the withdrawal of the casirivimab and  imdevimab (Ronapreve) neutralising monoclonal antibody (nMAB) combination as a  treatment option for patients hospitalised due to symptoms of COVID-19.

Further information and actions can be found in the COVID-19 therapeutic alert and interim clinical commissioning policy on the CAS alert website


Email newsletter

Want the latest pharmacy news and updates straight to your inbox?

Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.

Sign Up